

FORM PTO-1449				U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1053R1D1	Serial No. 09/705,579
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Fendly		
				Filing Date 02 Nov 2000	Group 1642	

## U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
CY	193	2002/0155527	24.10.02	Stuart et al.			
CY	194	5,514,554	07.05.96	Bacus, S.			
CY	195	5,571,894	05.11.96	Wels, W. et al.			
CY	196	5,587,458	24.12.96	King, C. et al.			
CY	197	5,730,977	24.03.98	Ooka et al.			
CY	198	5,783,404	21.07.98	Koski, R.			
CY	199	5,804,396	08.09.98	Plowman			
CY	200	5,846,749	08.12.98	Slamon et al.			
CY	201	5,856,089	05.01.99	Wang et al.			
CY	202	5,925,519	20.07.99	Jensen et al.			
CY	203	5,955,311	21.09.99	Rockwell et al.			
CY	204	6,165,464	26.12.00	Hudziak et al.			
CY	205	6,267,958	31.07.01	Andya et al.			
CY	206	6,270,765	07.08.01	Deo et al.			
CY	207	6,387,371	14.05.02	Hudziak et al.			
CY	208	6,395,272	28.05.02	Deo et al.			
CY	209	6,399,063	04.06.02	Hudziak et al.			
CY	210	6,407,213	18.06.02	Carter et al.			
CY	211	6,458,356	01.10.02	Arakawa et al.			
CY	212	6,512,097	28.01.03	Marks et al.			

## FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
CY	213	1,006,194	07.06.00	EPO				
CY	214	412,116	29.11.95	EPO				
CY	215	444,181	31.10.01	EPO				
CY	216	494,135	10.04.96	EPO				
CY	217	502,812	14.08.96	EPO				
CY	218	554,441	27.01.99	EPO				
CY	219	656,367	07.06.95	EPO				
CY	220	WO 87/07646	17.12.87	PCT				
CY	221	WO 89/10412	02.11.89	PCT				
CY	222	WO 91/02062	21.02.91	PCT				
CY	223	WO 91/05264	18.04.91	PCT				
CY	224	WO 92/22653	23.12.92	PCT				
CY	225	WO 93/03741	04.03.93	PCT				

Examiner <i>C.Yaen</i>	Date Considered <i>8.23.04</i>
---------------------------	-----------------------------------

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office				Atty Docket No. P1053R1D1	Serial No. 09/705,579
				Applicant Fendly	
				Filing Date 02 Nov 2000	Group 1642
<b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)					

**FOREIGN PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
CY	226	WO 93/16185	19.08.93	PCT				
CY	227	WO 94/10202	11.05.94	PCT				
CY	228	WO 96/07321	14.03.96	PCT				
CY	229	WO 96/16673	06.06.96	PCT				
CY	230	WO 96/30046	03.10.96	PCT				
CY	231	WO 96/40789	19.12.96	PCT				
CY	232	WO 97/00271	03.01.97	PCT				
CY	233	WO 97/04801	13.02.97	PCT				
CT	234	WO 98/02463	22.01.98	PCT				
CY	235	WO 98/18489	07.05.98	PCT				
CY	236	WO 98/45331	15.10.98	PCT				
CY	237	WO 99/31140	24.06.99	PCT				

**RECEIVED**

JUN 12 2003

TECH CENTER 1600/2900

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

CY	238	Burstein et al., "Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer" <u>Journal of Clinical Oncology</u> 19(10):2722-2730 (May 15, 2001)
CY	239	Chan et al., "Multinational phase II study of navelbine (N) and herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC)" (Abstract #434, SABCS Meeting 2002)
CY	240	Dermer, G., "Another anniversary for the war on cancer" <u>Biotechnology</u> 12:320 (1994)
CY	241	Filipovich et al., "Chemotherapy with trastuzumab plus vinorelbine in patients with erb-B2 overexpressed tumor is active in metastatic breast cancer" (Abstract #436, SABCS Meeting 2002)
CY	242	Jain, R., "Vascular and interstitial barriers to delivery of therapeutic agents in tumors" <u>Cancer and Metastasis Reviews</u> 9:253-266 (1990)
CY	243	Kaufman et al., "Phase I trial of Herceptin (H) and navelbine (Nvb) for patients with HER-2/neu (+) advanced breast cancer" (Abstract #431, SABCS Meeting 2002)
CY	244	Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo" <u>Nature</u> 362:841-844 (1993)
CY	245	Kim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" <u>Growth Factors</u> 7(1):53-64 (1992)
CY	246	Konecny et al., "Therapeutic advantage of chemotherapy drugs in combination with HERCEPTIN against human breast cancer cells with HER-2/NEU overexpression" <u>Breast Cancer Res Treat</u> (Abstract No. 467) 57:114 (1999)
CY	247	Li et al., "Monoclonal Antibodies to Recombinant Human Vascular Endothelial Growth Factor" <u>J. Cell. Biochem. Suppl.</u> 15, part F:251 (1991)
CY	248	Pietras et al., "Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs" <u>Oncogene</u> 17(17):2235-2249 (Oct 29, 1998)

Examiner	Date Considered
C.Yuen	8.23.04
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	